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 Introduction 
 Inherited retinal dystrophies (IRD) are heterogeneous 
disorders characterized by a progressive loss of visual 
acuity (VA) and deterioration of the visual field (VF). He-
reditary retinal dystrophies are often monogenic  [1] . 
They can manifest at any age, but mostly affect young 
people and lead to blindness when the patient is at his or 
her most productive age. To date, therapeutic possibilities 
for IRD are limited. Nevertheless, a few treatment ap-
proaches have shown promise, such as: RPE65 gene re-
placement therapy for Leber’s congenital amaurosis 
(LCA)  [2–5] , genetic targeting of bipolar and/or ganglion 
cells with engineered photo-gates  [6] or light-sensitive 
proteins such as channelrhodopsin-2  [7] , exploitation of 
the protective effect of the neurotrophic factor  [8] , and 
microelectronic retinal prostheses  [9, 10] . 
 These advances in the treatment of IRD suggest that 
improved understanding of the onset of IRD will aid in 
the development of clinical applications. Epidemiological 
data on IRD in Europe is currently limited to blindness 
and the most common types of retinitis pigmentosa (RP) 
 [11–15] . Only a few studies have reported on parameters 
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 Abstract 
 The present retrospective study compared initial visual 
symptom patterns in inherited retinal dystrophies (IRD) on 
the basis of records of 544 patients diagnosed with a wide 
variety of IRD at the Tuebingen University Eye Hospital from 
2005 to 2008. Age at first onset of symptoms was noted, and 
the following clinical data were analyzed: visual acuity (VA), 
night vision disturbances, photophobia, onset of visual field 
defects, best corrected VA, and types of visual field defects. 
Median age at visual symptom onset was defined with 25th 
and 75th percentiles and compared in 15 IRD types. The main 
trends in VA changes in retinitis pigmentosa and cone-rod 
dystrophies were identified. This study was the first to com-
bine disease history and clinical data analysis in such a wide 
variety of IRD. It showed that patterns of initial symptoms in 
IRD can provide extra clues for early differential diagnosis 
and inclusion of IRD patients in clinical trials. 
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such as age at disease onset and geographic distribution 
 [16, 17] . Age at the onset of night blindness in the most 
frequent types of IRD has been examined in an earlier 
study  [18] , which however was carried out on a relatively 
small group, and did not analyze other visual symptoms 
and focus on the different types of IRD.
 A better understanding of symptomatic patterns at the 
time of disease onset and their differences in a variety of 
IRD should therefore make it possible to identify IRD pa-
tients who can benefit from treatment during early dis-
ease stages. The aim of our study was therefore to com-
pare early patterns of typical visual symptoms onset in 
the different types of IRD.
 Materials and Methods 
 Records of 544 patients with IRD at the University Eye Hospi-
tal in Tuebingen, Germany, from 2005 to 2008 were selected. Pa-
tients with the following diagnoses were included: RP; Stargardt 
disease (STD); central areolar choroidal dystrophy (CACD); cone 
dystrophies (CD); cone-rod dystrophies (CRD); pseudovitelli-
form, vitelliform and pattern macular dystrophy (MD), Bardet-
Biedl syndrome (BBD); Usher syndrome I (USH I) and II (USH 
II); choroideremia (CHRD); LCA. Disease history was reported 
by the patient or collected from medical records using a standard-
ized approach. The information on age of symptom onset as re-
ported by the patient or parents (in the case of early-onset IRD), 
or as diagnosed by an ophthalmologist was recorded at the first 
visit to the hospital and checked for consistency on the subsequent 
visit. Records that did not contain a final diagnosis or a full his-
tory of the disease were excluded. The records were transferred to 
Ophthabase  [19, 20] . General information included sex and age at 
first visit. This was necessary to compare sex distributions be-
tween IRD groups and to estimate the latency between VA de-
crease and ophthalmological examination. IRD-specific data in-
cluded age at first onset of visual symptoms (i.e. noticeable loss of 
VA, night vision disturbances, glare sensitivity, signs of restricted 
VF), age at first clinical diagnosis, age at first experienced VA de-
crease, and age at first ophthalmological examination of patients 
with RP and CRD. Clinical data included best corrected VA 
(BCVA) in decimals and static and kinetic perimetry (Octopus 
101 and Goldmann) as graded by the examining ophthalmologist. 
Some RP patients were genetically tested, and an inheritance 
mechanism was verified in a fraction of them. RP was described 
as simplex (SIM-RP) when no inheritance pattern was detected, 
and as non-specified inheritance (RP-NSI) when genetic testing 
was not done. 
 Informed consent was obtained from all study participants in 
accordance with the Declaration of Helsinki. The study protocol 
was approved by the Ethics Commission of the Medical Faculty, 
University of Tuebingen. Statistical analysis was performed with 
JMP 8.0.2 (SAS Institute Inc., Cary, N.C., USA). Non-normally 
distributed data were represented by medians (25th and 75th per-
centiles), and approximately normally distributed data by means 
(SD). Age at first diagnosis and first subjective visual symptoms 
were stratified by main ophthalmic diagnosis. 
 Results 
 Records of 544 patients with STD (n = 69), CACD 
(n = 7), CD (n = 37), CRD (n = 13), MD (n = 17), RP (n = 
276), BBD (n = 13), USH I (n = 5), USH II (n = 18), CHRD 
(n = 21), and LCA (n = 15) were studied. Men (n = 302) 
were more prevalent than women (n = 242) in the study 
population ( fig.  1 a). Age distribution of the patients at 
first visit was approximately normal ( fig. 1 b): the mean 
age was 43.46 (SD = 18.34). The distribution at final di-
agnosis is shown in  figure 1 c. Genetic testing of RP pa-
tients showed that SIM-RP (n = 64, 41%) was the most 
frequent type of RP followed by X-linked (XL-RP) (n = 
36, 23%), autosomal dominant (ADRP) (n = 30, 19%), and 
autosomal recessive (ARRP) (n = 27, 17%). 
 We obtained data on the number of genes causing dif-
ferent types of IRD from OMIM  [21] and calculated a 
robust statistic of the variability in age at major visual 
symptom onset by taking the difference between the 75th 
and 25th percentiles. For each symptom, there is a very 
low correlation between the age at onset variability and 
the number of genes that cause the disease. Pearson’s cor-
relation coefficient ranged from 0.05 (for age at photo-
phobia onset) to 0.34 (for age at VA onset).
 An age comparison at the onset of night blindness and 
photophobia is shown in  figure 1 f and g, respectively.  Fig-
ure 1 h and i show a comparison of ages at the time of first-
reported VA decrease and VF defects (both of which are 
strongly anti-correlated with the performance of daily 
activities  [22] ). A summary of median age at the onset of 
typical IRD symptoms is shown in  table 1 .
 To highlight differences in the patterns of early symp-
toms of RP and CRD, BCVA was plotted vs. the difference 
between age at first visit to an ophthalmologist and the age 
of the first experienced decrease in VA in RP and CRD 
( fig. 1 d, e). CRD patients (n = 66) and RP (n = 42) patients 
responded to written questions concerning first decrease 
in VA: ADRP (n = 6), ARRP (n = 5), early-onset RP (n = 
18), SIM-RP (n = 9), and XL-RP (n = 4). Patient ages and 
BCVA at first visit were obtained from their records. Most 
patients had a combination of central (n 1 ) and peripheral 
 Fig. 1.  a Sex distribution of the study population, stratified by di-
agnosis.  b Age distribution of patients with IRD.  c Distribution of 
final diagnosis.  d A scatter plot showing BCVA versus the latent 
period in RP patients.  e A scatter plot showing BCVA versus the 
latent period in CRD patients.  f Box plots of age of night blindness 
onset in IRD.  g Box plots of photophobia onset in IRD.  h Box plots 
of initial VA decrease in IRD.  i Box plots of age at onset of VF de-
fects in IRD.  j VF defects stratified by diagnosis. 
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(n 2 ) VF defects, i.e. RP (n 1 = 152 and n 2 = 45) and CRD 
(n 1 = 23 and n 2 = 31). Central scotoma was more typical in 
STD (n = 48), CD (n = 23), and MD (n = 7) ( fig. 1 f).
 Discussion  
 Men were more prevalent than women (male/female 
ratio: 1:3), which corresponds to results obtained previ-
ously  [15, 16] . The higher number of men can be explained 
by patients with X-linked retinal disorders such as CHRD 
and XL-RP in the study population. The majority of pa-
tients were between 21 and 40 years of age, which under-
scores the public health importance of IRD, and is in line 
with previous findings  [23] .
 RP, STD, CRD, and CD were the most frequent diag-
noses. Patients with USH II were 3 times more frequent 
than USH I patients, which is in line with earlier results 
 [11] . SIM-RP was the most widespread form of RP, cor-
responding to previous studies  [24] , followed by XL-RP. 
A similar frequency of XL-RP was observed in a nation-
wide study in Denmark  [25] . Our results showed a very 
low correlation between the age at onset variability and 
the number of genes that cause the disease.
 Early night blindness was detected in patients with 
LCA, BBD, STD, XL-RP, USH I, and RP-NSI; this corre-
sponds to previous findings  [18] . Considerable age varia-
tion was noted at the onset of night blindness in patients 
with ADRP; this is in line with data obtained at the Uni-
versity of California Los Angeles, where the mean age at 
first examination was 35 years, with a mean disease dura-
tion of 19.2 years. CD and CRD patients had an earlier 
onset of photophobia and VA decrease than those with 
other diseases because of the predominant involvement 
of the cones  [26] . Patients with XL-RP reported a VA de-
crease and VF defects earlier than those with other types 
of RP; this is supported by other studies which have re-
ported on severe and/or early VA decrease and VF loss 
and night blindness onset in such patients  [27–29] .
 Analysis of BCVA measured at first visit versus latency 
showed that patients with RP and better BCVA tended to 
delay their visit to the ophthalmologist for many years. 
The fact that some patients with a good BCVA visited an 
ophthalmologist early on in the disease can be explained 
by the onset of other major symptoms. Two main observa-
tions are apparent in  figure 1 d and e: (1) there is a wide 
variation in the period between onset of symptoms and 
first visit to an ophthalmologist, both for RP and CRD, 
and (2) there is a trend relating BCVA and latency for 
CRD, but this trend is less apparent for RP. Patients with 
early-onset RP and SIM-RP generally had a more stable 
BCVA than those with other RP types. CRD patients had 
both a shorter latent period than those with RP and on 
average a worse BCVA at their first visit. Our findings in-
dicate that patients with CRD normally experience a se-
vere VA loss earlier than those with RP  [26] . Previous 
Table 1.  Age at onset of typical IRD symptoms
IRD types Night blindness 
onset
Initial VA
decrease
Photophobia onset Onset of VF 
defects
First diagnosis
ADRP 17 (0, 35.5) 25 (8.8, 49.8) 34 (27.5, 44.5) 33 (21.5, 43.5) 27 (15.5, 57)
ARRP 20 (9, 30) 21 (13.5, 46.5) 25.5 (9.3, 33) 25 (13, 37) 16.5 (14.25, 22)
SIM-RP 30.5 (15, 46) 28.5 (16, 44) 38 (25.3, 9.8) 34 (21, 47) 31 (16.25, 70.3)
XL-RP 16 (7, 25) 16 (6, 28) 19 (16, 32.3) 17 (7, 30.3) 20 (20, 79.5)
RP-NSI 18 (10, 40) 15 (6, 41.5) 25 (24.8, 40.3) 20 (10, 37) 24.5 (24.5, 55)
BBD 7 (3, 8.75) 5 (2.5, 12) 3 (1, 15.5) 6.5 (3.3, 18) 5.6 (3.5, 7)
CACD 47 (46.5, 58) 44 (32, 49) 45 (35, 50) 52 (39, 56) 55.5 (43.25, 9.75)
CHRD 18 (10, 23) 36.5 (11.5, 42.8) 24 (15.8, 40) 30 (15, 41) 16.5 (10, 43)
CD 20 (10, 40) 12.5 (5.75, 38.3) 12 (5, 31) 30 (25, 40) 19 (10, 45.3)
CRD 18 (7, 32) 10 (6.5, 34) 20 (8, 40.5) 22 (9, 37.3) 12 (6, 26.5)
MD 27 (19.25, 36) 27 (7.5, 39.75) 19.5 (7.5, 27.8) 40 (30, 51) 33.5 (27.25, 51.75)
STD 14 (12, 28) 17.5 (10, 28) 18 (10, 31) 24.50 (15.8, 34.3) 23 (15, 32.5)
USH I 23 (7, 36.5) 25 (8.5, 37) 27.17 (16, 32) 11.5 (6.25, 17.8) 14 (7, 15)
USH II 16 (6, 24.5) 30 (16.3, 36.3) 35 (19.3, 42.8) 24 (17, 31.5) 23.50 (19, 34)
LCA 3 (2, 6) 3 (2, 6) 11.5 (4, 15.3) 3 (3, 6) 3 (3, 6)
Data presented as median ages (years) with 25th and 75th percentiles in parentheses.
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studies in RP patients have shown that VA can remain 
normal in individuals with advanced stages of the disease, 
even when only a small island of the VF remains  [23] . 
Since patients with RP are known to suffer irreversible and 
progressive loss of VF as they age  [30] , we speculate that 
the early decrease in VA and the shorter latent period 
found in some RP patients can be explained by a combina-
tion of central and peripheral VF defects that can lead to 
the subjective perception of lowered VA. Interestingly, the 
trend we observed when plotting BCVA versus the latent 
period in CRD was very similar to the trend of VF areas 
plotted against the period between first experience of VF 
defects and the time of the ophthalmological examination 
in RP. The trend of VF changes in RP patients was first 
noted by Massof et al.  [31] , who used a two-stage hypoth-
esis to explain the natural course of RP. 
 Overall, the study identifies variability in age at onset 
of major visual symptoms in fifteen IRD types and de-
fines the diagnostic reliability of these parameters for 
each IRD group. To the best of our knowledge there are 
no other studies that have performed a similar compara-
tive analysis using such a wide variety of IRD diagnoses. 
The results of this analysis suggest that patients with RP 
tend to delay their first visit to an ophthalmologist, where-
as others undergo ophthalmological examination even if 
their BCVA is relatively good. Clinical data suggest that 
early visits to an ophthalmologist can be explained by a 
combination of central and peripheral VF defects. 
 This study also showed that patients with CRD tend to 
have worse BCVA and visit an ophthalmologist earlier 
than those with RP. Interestingly, we observed a similar-
ity between the trend of BCVA change in CRD and VF 
change in RP patients, which was not previously noted in 
the literature.
 This study underlines the phenotypical heterogeneity 
observed between different RP types and suggests that 
XL-RP patients had a rapid BCVA decrease and onset of 
VF defects, whereas early-onset RP and SIM-RP had 
more stable BCVA. Previous publications have mostly fo-
cused on phenotypical peculiarities in RP patients that 
carry a certain genetic mutation  [32–34] . These studies 
did not compare symptom onsets or disease progression 
between different types of IRD. In contrast, our study 
provides new information on disease onset patterns and 
a comparison of age at symptoms onset in different IRD 
types, which can be useful in clinical practice as a diag-
nostic clue prior to genetic testing.
 Our study had some limitations: it was retrospective 
and genetic data was available from a limited number of 
patients. Data on the history of the disease were mostly 
based on the patients’ subjective perceptions. Neverthe-
less, the data were collected over a 4-year period in a high-
ly standardized manner, which enabled us to include a 
relatively large sample size of patients with rare forms of 
IRD. Patients from all over Germany were represented in 
the study population, indicating that the results of the 
study will generalize. Our future research will be devoted 
to the linkage of phenotypical data with detailed genetic 
testing results in a wide variety of IRD, which will allow 
a more precise phenotype-genotype differentiation.
 Acknowledgements 
 We thank the team of senior resident ophthalmologists who 
examined the patients. This study was supported by a stipend 
from Kerstan Stiftung and a travel scholarship from Pro-Retina 
Deutschland e.V.
 Disclosure Statement 
 No conflicts of interest exist on the part of any of the authors.
 
 References 
 1 Bok D: Contributions of genetics to our un-
derstanding of inherited monogenic retinal 
diseases and age-related macular degenera-
tion. Arch Ophthalmol 2007; 125: 160–164. 
 2 Ashtari M, Cyckowski LL, Monroe JF, Mar-
shall KA, Chung DC, Auricchio A, Simonel-
li F, Leroy BP, Maguire AM, Shindler KS, 
Bennett J: The human visual cortex responds 
to gene therapy-mediated recovery of retinal 
function. J Clin Invest 2011; 121: 2160–2168. 
 3 Bennett J: Gene therapy for Leber congenital 
amaurosis. Novartis Found Symp 2004; 255: 
 195–202; discussion 202–197. 
 4 Jacobson SG, Aleman TS, Cideciyan AV, Su-
maroka A, Schwartz SB, Windsor EA, Tra-
boulsi EI, Heon E, Pittler SJ, Milam AH, Ma-
guire AM, Palczewski K, Stone EM, Bennett 
J: Identifying photoreceptors in blind eyes 
caused by RPE65 mutations: prerequisite for 
human gene therapy success. Proc Natl Acad 
Sci U S A 2005; 102: 6177–6182. 
 5 Koenekoop RK: Why some photoreceptors 
die, while others remain dormant: Lessons 
from RPE65 and LRAT associated retinal 
dystrophies. Ophthalmic Genet 2011;  32: 
 126–128. 
 6 Szobota S, Gorostiza P, Del Bene F, Wyart C, 
Fortin DL, Kolstad KD, Tulyathan O, Vol-
graf M, Numano R, Aaron HL, Scott EK, 
Kramer RH, Flannery J, Baier H, Trauner D, 
Isacoff EY: Remote control of neuronal activ-
ity with a light-gated glutamate receptor. 
Neuron 2007; 54: 535–545. 
 7 Nagel G, Szellas T, Huhn W, Kateriya S, Ad-
eishvili N, Berthold P, Ollig D, Hegemann P, 
Bamberg E: Channelrhodopsin-2, a directly 
light-gated cation-selective membrane chan-
nel. Proc Natl Acad Sci USA 2003;  100: 
 13940–13945. 
 Prokofyeva/Troeger/Wilke/Zrenner
 
Ophthalmologica 6
 8 Talcott KE, Ratnam K, Sundquist SM, Lu-
cero AS, Lujan BJ, Tao W, Porco TC, Roorda 
A, Duncan JL: Longitudinal study of cone 
photoreceptors during retinal degeneration 
and in response to ciliary neurotrophic fac-
tor treatment. Invest Ophthalmol Vis Sci 
2011; 52: 2219–2226. 
 9 Stieglitz T: Development of a microma-
chined epiretinal vision prosthesis. J Neural 
Eng 2009; 6: 065005. 
 10 Zrenner E, Bartz-Schmidt KU, Benav H, 
Besch D, Bruckmann A, Gabel VP, Gekeler 
F, Greppmaier U, Harscher A, Kibbel S, Koch 
J, Kusnyerik A, Peters T, Stingl K, Sachs H, 
Stett A, Szurman P, Wilhelm B, Wilke R: 
Subretinal electronic chips allow blind pa-
tients to read letters and combine them to 
words. Proc Biol Sci 2011; 278: 1489–1497. 
 11 Spandau UH, Rohrschneider K: Prevalence 
and geographical distribution of Usher syn-
drome in Germany. Graefes Arch Clin Exp 
Ophthalmol 2002; 240: 495–498. 
 12 Peterlin B, Canki-Klain N, Morela V, Stirn B, 
Rainer S, Cerar V: Prevalence of retinitis pig-
mentosa in Slovenia. Clin Genet 1992; 42: 
 122–123. 
 13 Rosenberg T, Haim M, Hauch AM, Parving 
A: The prevalence of Usher syndrome and 
other retinal dystrophy-hearing impairment 
associations. Clin Genet 1997; 51: 314–321. 
 14 Tous HM, Izquierdo NJ: Retinitis pigmen-
tosa in Puerto Rico. P R Health Sci J 2006; 25: 
 315–318. 
 15 Krumpatszky HG: Blindness incidence in 
Germany: a population-based study from 
Württemberg-Hohenzollern. Ophthalmo-
logica 1999: 176–182. 
 16 Ayuso C, Garcia-Sandoval B, Najera C, Val-
verde D, Carballo M, Antinolo G: Retinitis 
pigmentosa in Spain: the Spanish Multicen-
tric and Multidisciplinary Group for Re-
search into Retinitis Pigmentosa. Clin Genet 
1995; 48: 120–122. 
 17 van den Born LI, Bergen AA, Bleeker-Wage-
makers EM: A retrospective study of regis-
tered retinitis pigmentosa patients in the 
Netherlands. Ophthalmic Paediatr Genet 
1992; 13: 227–236. 
 18 Heckenvlively JR YS, Friedman LH, Oversier 
JJ: Clinical findings and common symptoms 
in retinitis pigmentosa. Am J Ophthalmol 
1988: 504–511. 
 19 Tröger E, Prokofyeva E, Wilke R, Zrenner E: 
Reusability in patient registries-implamen-
tion of genericextensible web-based patient 
registry system; in Azevedo L LA (ed): Sec-
ond International Conference on Health 
Informatics, HEALTHINF 2009. Porto, 
INSTICC, 2009, pp 438–441. 
 20 Tröger E, Wilke R, Prokofyeva E, Zrenner E: 
Ophthabase: a generic extensible patient reg-
istry system. Acta Ophthalmologica 2008; 
 86(suppl s243):0. 
 21 OMIM (an online catalog of human genes 
and genetic disorders). www.omim.org (ac-
cessed 11 June 2011). 
 22 Szlyk JP, Fishman GA, Alexander KR, Rev-
elins BI, Derlacki DJ, Anderson RJ: Relation-
ship between difficulty in performing daily 
activities and clinical measures of visual 
function in patients with retinitis pigmen-
tosa. Arch Ophthalmol 1997; 115: 53–59. 
 23 Hartong DT, Berson EL, Dryja TP: Retinitis 
pigmentosa. Lancet 2006; 368: 1795–1809. 
 24 Haim M: Prevalence of retinitis pigmentosa 
and allied disorders in Denmark. III. Hered-
itary pattern. Acta Ophthalmol (Copenh) 
1992; 70: 615–624. 
 25 Haim M: Epidemiology of retinitis pigmen-
tosa in Denmark. Acta Ophthalmol Scand 
suppl 2002; 233: 1–34. 
 26 Hamel CP: Cone rod dystrophies. Orphanet 
J Rare Dis 2007; 2: 7. 
 27 Ferreira PA: Insights into X-linked retinitis 
pigmentosa type 3, allied diseases and un-
derlying pathomechanisms. Hum Mol Genet 
2005; 14(spec No. 2):R259–R267. 
 28 Kaplan J, Bonneau D, Frezal J, Munnich A, 
Dufier JL: Clinical and genetic heterogeneity 
in retinitis pigmentosa. Hum Genet 1990; 85: 
 635–642. 
 29 Prokisch H, Hartig M, Hellinger R, Meit-
inger T, Rosenberg T: A population-based 
epidemiological and genetic study of X-
linked retinitis pigmentosa. Invest Ophthal-
mol Vis Sci 2007; 48: 4012–4018. 
 30 Akeo K, Saga M, Hiida Y, Oguchi Y, Okisaka 
S: Progression of visual field loss in patients 
with retinitis pigmentosa of sporadic and au-
tosomal recessive types. Ophthalmic Res 
1998; 30: 11–22. 
 31 Massof RW, Finkelstein D: A two-stage hy-
pothesis for the natural course of retinitis 
pigmentosa; in Zrenner E, Krastel H, Goebel 
HH (eds): Research in Retinitis Pigmentosa. 
Oxford, Pergamon Press, 1987, vol 62, pp 29–
58. 
 32 Audo I, Friedrich A, Mohand-Said S, Lance-
lot ME, Antonio A, Moskova-Doumanova V, 
Poch O, Bhattacharya S, Sahel JA, Zeitz C: 
An unusual retinal phenotype associated 
with a novel mutation in RHO. Arch Oph-
thalmol 2010; 128: 1036–1045. 
 33 Vaclavik V, Gaillard MC, Tiab L, Schorderet 
DF, Munier FL: Variable phenotypic expres-
sivity in a Swiss family with autosomal dom-
inant retinitis pigmentosa due to a T494m 
mutation in the PRPF3 gene. Mol Vis 2010; 
 16: 467–475. 
 34 Bessant DA, Holder GE, Fitzke FW, Payne 
AM, Bhattacharya SS, Bird AC: Phenotype of 
retinitis pigmentosa associated with the Ser-
50Thr mutation in the NRL gene. Arch Oph-
thalmol 2003; 121: 793–802. 
 
